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RISK FACTORS FOR NONADHERENCE TO OUTPATIENT APPOINTMENTS 
IN LUNG CANCER PATIENTS AND A REVIEW OF THE PATIENT 
NAVIGATION SYSTEM: A CASE-CONTROL STUDY 
 
RACHEL KRIEGER 
ABSTRACT 
Background: There is a need to identify the populations at high risk of nonadherence to 
outpatient lung cancer appointments in order to reduce the delay from diagnosis to 
treatment. The patient navigation system, which helps patients with barriers navigate the 
health care system, was examined to see if the correct high-risk groups were being 
addressed. 
Methods: A case-control study with 195 subjects from the lung cancer clinics at Boston 
Medical Center (BMC) was conducted examining three nonadherence case groups: no-
shows (n=40), cancelations (n=64) and combined (n=20). Nonadherence was defined as 
any patient who was a no-show for at least one appointment or who canceled more than 
one appointment over the three month study period. The combined group incorporated 
both of these factors. The patients were stratified by 10 patient characteristics, including 
patient navigation. Odds ratios (ORs) and 95% confidence intervals (CIs) were used for 
the analysis. A second analysis was done on patients in the patient navigation program 
(n=33) to determine if the high risk groups identified were being addressed. This was 
done using ORs and 95% CIs. 
Results: This study has shown that there are certain patient groups in the lung cancer 
clinics at BMC that are at higher risk of being nonadherent to lung cancer outpatient 
		 vi
appointments. Among those are Hispanic/Latino patients, Spanish and Haitian Creole 
speaking patients, small cell lung cancer (SCLC) patients, and those patients who have 
Medicaid, and with late stage lung cancer patients at significantly higher risk (no-shows: 
OR-5.26 (1.85, 14.95), cancelations: OR-2.49 (1.12, 5.54), combined: OR-12.49 (1.48, 
105.46)). Patients in the patient navigation system were also found to be at significantly 
higher risk of nonadherence (no-shows: OR-3.85 (1.72, 8.65), cancelations: OR-4.13 
(1.89, 9.00), combined: OR-5.15 (1.93, 13.72)) than those not in the program.  Some 
patients were also found to be at significantly decreased odds of nonadherence, including 
those who were: 1000-1999 days post diagnosis (no-shows: OR-0.14 (0.03, 0.59), 
cancelations: OR-0.20 (0.06, 0.65), combined: OR-0.07 (0.01, 0.64)); 2000-2999 days 
post diagnosis (no-shows: OR-0.09 (0.01, 0.80), cancelations: OR-0.06 (0.01, 0.50)); 
aged 71-75 (cancelations: OR-0.25 (0.08, 0.79)). The subset analysis with the patient 
navigation data yielded no statistically significant results.  
Conclusions: The study identified high-risk populations within the total lung cancer 
population at BMC that should be addressed by the patient navigation program. This 
study demonstrated that while the program does have its flaws, it is decreasing the odds 
of nonadherence of many of the high-risk populations. 
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INTRODUCTION 
 
Lung Cancer 
Lung cancer is the leading cause of cancer death in the United States, with 
approximately 150,000 deaths each year.1 Lung cancer involves the uncontrolled growth 
of abnormal cells in one or both lungs. It starts in the cells lining the bronchi and in other 
parts of the lung such as the bronchioles or alveoli. These abnormal cells do not carry out 
the functions of normal lung cells and do not develop into healthy lung tissue.2 As they 
grow, the abnormal cells can form tumors and interfere with the functioning of the lung.  
The most common cause of lung cancer is tobacco from smoking, which causes 
87% of lung cancers in the United States.  Other important risk factors include asbestos, 
radon, air pollution, industrial substances, genetics, tuberculosis and military service.3 
The benefits of early diagnosis have been well-documented across the years, but 
routine screening for lung cancer, even in high-risk individuals has not been 
recommended until recently. Individuals at high risk for lung cancer can be defined as 
any smoker, current or former, with at least 20 pack years of smoking.4  When patients 
are screening, there are two major types of lung cancer with which individuals may be 
diagnosed: Non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). 
 
Non-Small Cell Lung Cancer 
NSCLC is a disease in which malignant (cancer) cells form in the tissues of the 
lung.2 NSCLC accounts for approximately 85% of lung cancers, including tumors such as 
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squamous cell carcinomas4 (also called epidermoid carcinoma)2, which form in the lining 
of the bronchial tubes; adenocarcinomas, which are a type of tumor that forms in 
glandular structures (and is the most common form of lung cancer in the United States 
among bother men and women); large-cell carcinoma4, which are non-small cell lung 
cancers that are neither adenocarcinomas nor epidermoid cancers2; and, any poorly 
differentiated variants that have not yet developed into one of the other NSCLC 
variations, otherwise referred to as NSCLC not otherwise specified (NSCLC-NOS).4 The 
NSCLC-NOS designation is used when the cancer is poorly differentiated or testing to 
determine the variation of NSCLC is inconclusive.4   
NSCLC is staged I through IV, with the stages referring to the degree of 
progression of the cancer.5  Table 15,6 illustrates NSCLC staging, with a description of the 
progression of the disease.  The American Joint Committee on Cancer’s Classification of 
Malignant Tumors (AJCC TNM) allows for a very specific staging of the cancer.  The 
AJCC TNM are three components of the staging, with the “T” expressing the size of the 
primary tumor, the “N” describing whether or not there is regional lymph node metastasis 
and the “M” expressing the existence or absence of distant metastasis.  Each is then 
followed by a suffix, usually a number, expressing the extent of each category, with a 
higher number expressing a worse prognosis: T can be followed by is or 0-4; N can be 
followed by 0-3; and, M can be followed by 0 or 1.  The is suffix is an abbreviation for in 
situ, a type of cancer that has not yet invaded the surrounding tissue.6 Furthermore, the T 
and M categories may be broken down to include an a or b after the number for increased 
specificity.6,7   Appendix I7 contains the definitions of each AJCC TNM category. For 
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example, TisN0M0 describes a cancer without invasive tumor cells that has not spread to 
any lymph nodes and without any metastases.  Five-year survival rates range from 73% 
in stage 1A NSCLC patients to 9% in stage IIIB patients.8   The five-year survival rate in 
patients with stage IV NSCLC is less than 4%.9 As stage increases, five-year survival rate 
decreases, due to the increase in tumor progression and worsening prognosis with 
increased stage.8,9 
 
Table 1: NSCLC Staging5,6 
 AJCC TNM Stage Tumor Location 
Stage 0 Tis N0 M0 Localized to lungs 
Stage IA T1 N0 M0 Localized to lungs 
Stage IB T2 N0 M0 Localized to lungs 
Stage IIA T1 N1 M0 Lungs and nearby lymph 
nodes 
Stage IIB T2 N1 M0 
T3 N0 M0 
Lungs and nearby lymph 
nodes 
Stage IIIA T1 N2 M0 
T2 N2 M0 
T3 N1 M0 
T3 N2 M0 
Lungs and lymph nodes on 
the same side of the chest as 
the original tumor 
Stage IIIB Any T  N3 M0 
T4  Any N M0 
 
Lungs and lymph nodes on 
the opposite side of the 
chest as the original tumor 
OR lymph nodes above the 
collar bone 
Stage IV Any T  Any N  M1 Both lungs, fluid 
surrounding the lungs or 
other organs of the body 
 
Small Cell Lung Cancer 
Approximately 10% to 15% of all lung cancers are SCLC, named for the size of 
the cancer cells when seen under a microscope.2 More precisely, SCLC is defined as “a 
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malignant epithelial tumour consisting of small cells with scant cytoplasm, ill-defined 
cell borders, finely granular nuclear chromatin, and absent or inconspicuous nucleoli”.10 
SCLC is also characterized by several abnormalities in DNA copy number. The most 
common SCLC patients are males over 70 years of age, with a history of heavy smoking 
and who have cardiovascular and pulmonary comorbidities.10  SCLC progresses 
extremely quickly and survival time without treatment can be as short as 2 to 4 months.  
Two-year survival rates are also lower than with many NSCLC patients, with 20-40% of 
limited stage patients  and only 5% of patients with extensive stage disease surviving to 2 
years.10 
	
Compared to NSCLC, SCLC is a more invasive and more rapidly growing form 
of cancer, although it is more responsive to some forms of treatment.11 SCLC has a much 
higher correlation with tobacco use and is almost exclusively found in smokers.11  
Originally, SCLC was diagnosed as either limited or extensive stage disease. Limited 
stage SCLC corresponds to AJCC TNM Stages I-III and extensive stage SCLC 
corresponds to Stage IV. SCLC can be staged I-IV with the same definitions as NSCLC 
with the AJCC TNM guidelines.12  It is now just as common to see SCLC diagnosed as 
stage I-IV. Table 212 illustrates how limited and extensive stages are classified.   
Staging of SCLC is performed using a multitude of tools, including: physical 
examination; routine blood counts and serum chemistries; a chest CT scan; a bone scan; a 
brain MRI or CT scan; and/or a PET scan.13, 14 PET scans, though originally used in 
patients who could have benefitted from thoracic radiation therapy, are now standard 
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practice for determining staging. The PET scan can be used instead of or in addition to a 
CT scan, to more accurately determine the SCLC stage as well as identify additional 
nodal metastases.  In one study using patients without metastases to the brain, PET scans 
were shown to have more sensitivity and specificity than CT scans.13  Another study used 
PET scans to document nodal metastases in 25% of patients who previously did not have 
any documented.15  
Table 2: SCLC Staging12  
 AJCC TNM Stage Tumor Location Other factors 
Limited Stage I-IIIB 
 
Confined to the 
hemithorax of origin, 
the mediastinum or 
the supraclavicular 
nodes 
 
 
Extensive Stage IV 
 
Tumor has spread 
beyond 
supraclavicular areas 
Malignant 
pleural 
effusions 
 
 
Diagnosis 
Lung cancer diagnoses are often done by morphology during resection, the 
surgery done to remove the tumor. Immunochemistry, the study of the molecular and 
biochemical mechanisms of immunology16, can also be used to differentiate between 
types of NSCLC in biopsy and cytology material.4, 10 
	
In some Phase 2, non-randomized studies screening chest CTs have been able to 
detect small tumors 12-15 mm in diameter. 17  These studies have been testing the benefit 
of screening for lung cancer in individuals at high risk for lung cancer and have shown 
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that a chest CT can detect 70-80% more of these small tumors than a chest X-ray.18   The 
National Lung Screening Trial, a randomized screening trial of 53, 454 high risk 
individuals (participants with a smoking history of at least 30 pack years), compared 
screening using chest X-ray and low-dose chest CT scan.19 Results demonstrated that, 
when comparing the accuracy to detect small tumors using a screening chest X-ray versus 
a screening chest CT scan, lung cancer mortality was reduced by 20% in the CT cohort.19 
 
Treatment 
Lung cancer can be treated using surgery, chemotherapy radiation, and other 
targeted treatments alone or in combination depending on the type and stage of the 
cancer.  The majority of patients with stage I, II, and IIIA NSCLC are treated with 
surgery to remove their tumors, followed by adjuvant chemotherapy to help prevent 
recurrence of the cancer.20  Chemotherapy may also be used as a neoadjuvant therapy to 
shrink the size of the patient’s tumor before surgery to aid in its removal. Stage IIIA 
NSCLC patients who are medically unfit to undergo surgery, or stage IIIB NSCLC 
patients, are commonly treated with chemotherapy and high-dose radiation.20  The 
standard of care for stage IV NSCLC patients is most often chemotherapy as their tumors 
have spread too extensively for removal by surgery to be a viable option.20  Radiation 
therapy is not usually used as the only form of treatment in patients with NSCLC but it 
can be used in conjunction with other treatments or to help alleviate symptoms.  Patients 
with stage II or IV NSCLC may also receive targeted treatments instead of or in addition 
to chemotherapy.20  Targeted treatments are able to specifically attack cancer cells, unlike 
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chemotherapy treatments which attack all dividing cells.  Bevacizumab is a commonly 
prescribed targeted treatment for some types of lung cancer.4, 20 
Bevacizumab is a monoclonal antibody that was approved in 2006 by the Food 
and Drug Administration for the treatment of non-squamous NSCLC, in conjunction with 
carboplatin and paclitaxel, two chemotherapeutic agents. It was approved for use as a 
first line treatment for “unresectable, locally advanced, recurrent or metastatic disease”.21 
Bevacizumab binds to vascular endothelial growth factor (VEGF) in order to prevent it 
from interacting with its receptors. This leads to reduction in tumor growth and improved 
delivery of chemotherapeutic agents to the tumor.  
Though the treatment for NSCLC and SCLC patients can be very similar, there 
are a few distinct differences. Patients with SCLC are always treated with chemotherapy, 
regardless of stage, because of how quickly the cancer can spread through the body.11  
Radiation therapy may be used to treat symptoms in patients whose cancer has spread 
throughout the body, but it is not used to cure the disease.11  One major difference in 
treatment between in NSCLC and SCLC is brain radiation therapy. In more than half of 
patients with SCLC, the cancer spreads to the brain. Accordingly, in many patients with 
limited small cell lung cancer who are responding well to chemotherapy, prophylactic 
brain radiation therapy is typically added at the end of chemotherapy treatment.22  
 
Patient Appointment Adherence 
There are many reasons that a patient may be nonadherent with their outpatient 
appointments.   A literature search revealed that psychiatric patients have been the main 
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population studied when looking at no-shows with outpatient appointments, while 
elective surgeries seem to be the focus of many appointment cancelation studies.  There 
have been few (of these types of) studies performed in cancer patients and even fewer 
targeting appointment adherence specifically in lung cancer patients.  
Psychiatric patients tend to have a higher rate of no-shows than other populations, 
with one study putting the rate as close to 20%.23 This is partially due to the social stigma 
associated with psychology appointments.  This study also found that the rates of no-
shows were higher in patients with Medicaid.23 No-shows were also shown to occur more 
frequently in appointments made with residents instead of attending physicians, whereas 
patients with long-standing relationships with their doctors were the most likely to show 
up to their appointments.23   
Many studies have shown that no-show rates are higher among younger patients 
of a lower-socioeconomic status.24  Patients with lower paid jobs may have a harder time 
getting off work or arranging child care.  These patients are also more likely to not show 
up if they perceive their condition as having improved that day.24 Additionally, the rates 
of no-shows increase as the time between scheduling and the appointment increase.25  A 
possible reason for this is that the longer a patient has to wait for their appointment, the 
less happy they are with that medical practititioner,26  and the less likely they are too see 
that health care provider.27  Lacy et al., compiled a list of patient explanations for not 
showing up to their scheduled appointments, including:  “inability to get an appointment 
right away, anxiety or fear about the cause of the symptoms and anticipated diagnostic 
tests, feeling disrespected, symptoms improving (or not getting worse), and lack of 
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understanding of the scheduling system.” 25  One of the few studies to look at missed 
appointments in cancer patients found that the most frequent reasons for missed follow-
up appointments in head and neck patients were transportation, ill-health and financial 
constraints.28 
A few studies have assessed different hospitals’ actions to mitigate the financial 
effects of no-shows. One study looked at the use of SMS text reminders to increase 
compliance with outpatient appointments.29  That study found that while the impact was 
modest, this plan of action did come with a mitigation of cost of approximately $13.13 
per no-show avoided.29, 30  Additionally, one psychiatric study found that simply asking 
patients when they wanted to come in for an appointment instead of scheduling a patient 
for the first available appointment resulted in a lower no-show rate.23   
Parikh et al. conducted a study to look at the effectiveness of automated telephone 
reminders in reducing no-shows.31  This study was done across numerous specialties at 
the Robert Wood Johnson University Medical Group.  The authors found that while the 
automated reminders were effective, a reminder from a clinic staff member was 
significantly more effective in reducing no-show rates (13.6% vs. 17.3%, p<0.01).31 The 
authors also found that cancelation rates were significantly higher in the groups that had a 
reminder, automated or from the clinic staff, than the group that received no reminder 
(p<0.004).31 This study ultimately demonstrated that, while reminding a patient about an 
appointment was effective in reducing the number of no-shows, the type of reminder was 
an extremely important factor to consider.31 
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Patients’ last-minute cancelations can cause trouble not only for a patient’s care, 
but also for the hospital.  A study by Penneys and Galser conducted in an urban 
university-based clinic, looked at same day cancelations and no-shows at a dermatology 
clinic.32 The authors found that the no-show rate was 17% and that the lowest rate of no 
shows when stratifying by insurance type, were in patients with commercial insurance 
and the highest were in patients with government-supported insurances.32 Lastly, the 
authors discovered that the rates of same-day cancelations were significantly higher in 
females than in males (9.2% versus 7.3%, p = 0.02).32 
 
Patient Navigation  
A patient navigation system is designed to assist patients in getting swift access to 
the healthcare they need in a manner they are able to understand. Patient navigation 
systems also work to decrease readmission rates.33  Specifically, oncology patient 
navigators aim to reduce the time between a suspicious discovery, diagnosis and 
treatment in vulnerable populations.34  This is referred to as the “critical window of 
opportunity to save lives from cancer”.34  According to the National Cancer Institute 
(NCI), the groups that benefit the most from patient navigation are the poor and 
uninsured, and those at high risk for late diagnosis.34  Patient navigation’s core principle 
is to eliminate barriers to healthcare in underserved populations by creating a personal 
relationship with the patient.34  The navigators follow patients though their treatment, 
assist with getting their questions answered, remind them of appointments and follow up 
with them afterward.34 
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The first patient navigation program in Harlem, NY was able to significantly 
increase early-stage breast cancer diagnoses and improve 5-year survival rates in an 
extremely poor population.35  The Boston Patient Navigation Research Program revealed 
that patient navigation resulted in a reduced time to cancer diagnosis in diverse inner city 
populations, such as in Boston, Massachusetts.36  
Patient navigation has received a lot of attention from the United States 
Government in recent years. On June 29, 2005, President George W. Bush signed the 
Patient Navigator Outreach and Chronic Disease Prevention Act.37  This act allowed the 
Secretary of Health and Human Services to make grants available to certain groups, “for 
the development and operation of demonstration programs to provide patient navigation 
services to improve health care outcomes”.37 The main purpose of the act was to create 
programs that would provide assistance to people with cancer and other chronic diseases 
by helping them navigate their way through the health care system. The patient 
navigators were meant to be non-medical workers that led the patients through the 
medical system with the goal of helping people stay healthier and survive longer.37 
Groups that were eligible for these original grants included public or nonprofit health 
centers, cancer centers, academic health centers, health facilities operated by the Indian 
Health Service, as well as many others.38   
The Patient Protection and Affordable Care Act, signed by President Barack 
Obama on March 23, 2010, extended the duration of the grant from three to four years 
authorizing appropriations through 2015.39 It also added a clause, which required the 
Secretary of Health and Human Services to ensure that patient navigators as the entity 
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receiving the grant, met minimum core proficiencies.  The core proficiencies are defined 
by each hospital or medical center that applies for the grant and are tailored towards the 
hospital department in which each navigator will be working.39   
In response to the Patient Protection and Affordable Care Act, the American 
College of Surgeons Commission on Cancer overhauled their Cancer Program Standards 
mandating that all cancer programs have patient navigation services in place by 2015 in 
order to obtain/maintain accreditation.40 According to these standards, patient navigation 
is defined as the: “individualized assistance offered to patients, families, and caregivers to 
help overcome health care system barriers and facilitate timely access to quality medical 
and psychosocial care and can occur from prior to a cancer diagnosis through all phases 
of cancer experience.”40 The navigation services must be evaluated annually and 
modified, if necessary, to address any newly recognized barriers.  The evaluation 
includes a list of identified heath barriers in the community, a list of the populations the 
program serves, a description of the patient navigation process, as well as many other 
measures for the success of the program and any planned future directions.40 
A patient navigation study conducted in six community health centers in Boston, 
Massachusetts found that the program reduced time from an abnormal screening to a 
cancer diagnosis in women in a “racially/ethnically diverse inner city population”.36 Each 
of the six health centers that participated in the study cared for a different minority and/or 
immigrant population, demonstrating that patient navigation was beneficial to the same 
degree in all underserved populations. The study also demonstrated that patient 
navigation was equally beneficial to all populations regardless of insurance status.36   
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In the hematology and oncology departments at Boston Medical Center (BMC), 
high risk patients can be referred to patient navigation by any employee who has contact 
(with the patient). This referral is up to the discretion of the employee and can be made if 
the employee identifies the patient as high risk for no-shows or cancelations while in 
treatment, based on family, social, medical, financial or any other factor.  The navigators 
in the BMC cancer center are referred to as Cancer Center Treatment Navigators 
(CCTNs).  Each newly referred case is reviewed by a CCTN then contacted (by the 
CCTN) to begin the process of identifying and addressing potential barriers.41 
 
Study Rationale 
In order for patients to achieve the best health and have the opportunity for 
optimal treatment results, it is important to identify patients who are at high risk of 
missing medical appointments.  Missed outpatient appointments may result in a delay in 
treatment, during which time a patient’s cancer may progress, making it harder or 
impossible to treat.42  Jensen et al., demonstrated that without missed appointments, the 
time between when a patient first notices a symptom and waits to contact a doctor was 
longest for patients in the United States.42 The authors also demonstrated that, without 
taking into account missed appointments, the time interval between diagnosis and 
treatment was sufficient for some patients to become clinically incurable.42 More 
remarkably, there was a significantly longer delay for patients with Stage III and IV 
cancer at the pre-hospital level.42 The ability to predict who is at the highest risk of 
nonadherence with outpatient appointments will allow hospitals to follow these patients 
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more closely through the use of patient navigation in an effort to try to prevent longer 
delays in treatment and the progression of disease in lung cancer patients.42  
 
Study Questions  
1. Primary Study Question: Which groups within the lung cancer patient 
population at BMC are at the highest risk for nonadherence with outpatient 
clinic appointments? 
2. Secondary Study Question: Is the patient navigation program currently 
assisting those groups who are at high risk for nonadherence? 
Objectives 
1. Objectives 
a. Primary Objective: Identify the groups at highest risk for nonadherence 
within the outpatient lung cancer population at BMC. 
b. Secondary Objective: Determine if the patient navigation program assists 
the groups at the highest risk for noncompliance within the outpatient lung 
cancer population at BMC.
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METHODS 
	
A case-control study reviewing lung cancer patients’ medical records and 
appointment schedules from BMC for October 2012-December 2012 was designed.  All 
data were obtained from the Boston Medical Center Clinical Data Warehouse.  The 
Clinical Data Warehouse used Logician, the Electronic Medical Record system at BMC, 
and the BMC Tumor Registry to obtain the data needed. The data obtained included the 
following patient characteristics:  
 Age (in 5 year intervals) 
 Race 
 Sex 
 Primary language spoken 
 Insurance status 
 Cancer type, stage and location 
 Length of time since diagnosis 
 Patient navigation status 
 Outpatient appointment status 
 Performance status 
 Whether the patient had another appointment at BMC the day of, before or after 
their lung cancer appointment. 
 
Lung cancer outpatient appointments were defined as any appointment 
specifically for the diagnosis, treatment or management of a patient’s lung cancer.  This 
could be done in the pulmonary clinic, the thoracic surgery clinic, any of the oncology 
clinics or any associated testing appointments such as pulmonary function tests or 
magnetic resonance imaging.  A three month study period was chosen due to the high 
number of outpatient appointments.  It was decided that the high amount of data collected 
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from a three month study period should provide enough data to form conclusions.  After 
the Clinical Data Warehouse finished collecting all of the data, it was stripped of all 
identifiers and sent to the investigator for analysis.  
The patients who attended all of their outpatient appointments from October-
December 2012 were used as the control subjects for those who showed nonadherence 
with their outpatient appointments.  Nonadherence was defined as any patient who was a 
no-show for at least one outpatient appointment or who canceled more than one 
appointment over the time period being studied.  A combined nonadherence group was 
also analyzed, looking at patients who had at least one no-show and canceled more than 
one appointment over the three month study period. Patients in the combined group were 
also included in the individual no-show and cancelation groups. Patients who only 
cancelled one appointment over the three month study period were considered adherent 
with their outpatient appointments. Patients who were bumped from their appointments 
during the study period were included in the control group for demographic reasons. 
Bumping was defined as having their appointments canceled by BMC. For the purpose of 
this study, patients were referred to as no-shows, as that is the term used in the clinic 
when a patient fails to show up for an appointment. 
The data were separated into four data sets, including: the cancelations, the no-
shows, those with both no-shows and cancelations, and the population as a whole.  Each 
data set was separated by demographic factors. Patient navigation status was determined 
by the number of navigation notes each patient had in their medical record. Patients with 
less than four navigation notes were considered to not be a part of the patient navigation 
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system because during the study period, patient navigators were making reminder calls to 
all eligible new patients that could have resulted in up to 3 navigation notes in the system.  
A better measure of a patient’s enrollment and participation in the patient navigation 
program was to have at least four notes in their medical record showing an increased 
interaction with a navigator.  
 
Statistical Analysis 
The nonadherence groups were compared to their control groups using odds ratios 
(OR) and 95% confidence intervals. A control group was made for each case group, by 
subtracting the number of people in each noncompliant group from the total population, 
creating three groups containing no nonadherent individuals.  The same was done for 
each patient characteristic group within the case groups to remove the nonadherent 
patients from the control groups.  For example, for the no-show cases, from the total 195 
patient, a control group was created by subtracting the 40 no-show patients from the 195 
to get 155 total patients.  Then, the 2 Asian no-show patients were subtracted from the 7 
in the total population to get 5 Asian patients in the no-show control group.  Patient 
navigation was treated as a patient characteristic for this analysis.  There were many odds 
ratios that could not be calculated due to a zero cell. Lack of cases or controls in any of 
the patient characteristics led to a zero cell. 
The patient navigation population was further analyzed to determine if the patient 
navigation program was addressing the correct populations.  The same analysis that was 
performed on the total population calculating the odds ratios and 95% confidence 
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intervals was repeated on the patient navigation program. Again, many odds ratios could 
not be calculated due to zero cells. The patient navigation analysis was compared to the 
total population analysis to determine if the patient navigation program was assisted high-
risk groups. 
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RESULTS 
	
Demographics 
There were a total of 195 patients and 749 appointments analyzed.  Of the 749 
appointments, there were 53 no-shows and 271 cancelations. Of the 195 patients, there 
were 40 individuals with at least one no-show, and 64 individuals with at least 2 canceled 
appointments.  There were a total of 20 subjects in the combined group who had at least 
one no-show appointment and at least 2 canceled appointments. Table 3 describes the 
breakdown of the total study groups.  The patient characteristics, were separated into 
different demographic characteristics to include: race separated into American Indian, 
Asian, black, Hispanic/Latino, Middle Eastern, other and white; sex separated into male 
and female; primary language spoken separated into Albanian, Arabic, 
Bengali/Hindi/Urdu, Chinese, English, Greek, Haitian Creole, Italian, Port Creole/Cape 
Verdean, Portuguese, Russian, Spanish and Vietnamese; age separated into five-year 
intervals from 35-40 to 85-90 and >90; time since diagnosis (days) was separated into 0-
24, 25-49, 50-99, 100-199, 200-299, 300-399, 400-99, 500-599, 600-699, 700-799, 800-
899, 900-99, 1000-1999, 2000-2999 and 3000-3999; cancer type was separated into 
adenocarcinoma, carcinosarcoma, NSCLC-NOS, squamous-cell carcinoma and SCLC; 
cancer stage was separated into IA, IB, IIA, IIB, IIIA, IIIB and IV; tumor location was 
separated into lower lobe, main stem bronchus, middle lobe, upper lobe, bilateral lungs, 
left lung, right lung; insurance status was separated into charity, commercial/private, 
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Medicaid, Medicare and multiple insurances; patient navigation was split into whether or 
not a patient was in the program. Each data set was separated by demographic factors to 
determine the prevalence of each demographic in the separate populations.   
Performance status, a clinician measure of quality of life and functional capacity 
in everyday life,43 was not included in the analysis.  High performance status, was found 
to be an indicator of reduced survival and poor response to chemotherapy.43  It was found 
that the performance statuses in the original dataset were not obtained from a standard 
time point or from a standard performance status scale and as such would not lead to any 
valid conclusions.  It was also found that the data for the day of, before or after 
appointments was coded in such a way that it did not allow for the differentiation 
between having another appointment and determining when that other appointment 
occurred (the day of, before or after).  As such, that data was not included in the analysis.  
Due to incomplete medical records, or records with certain characteristics marked as 
unknown, not all characteristics sum to that columns’ total.  
The demographics are an accurate representation of the patient population at 
BMC. The majority of the total patients (88%) are white or black with a diverse 
representation of other races. This same trend holds true with the percentage of black and 
white patients in the three case groups; no-show: 88%; cancelations: 89%; and, 
combined: 80%. The sex breakdown in the total population consists of slightly more 
females than males (54% vs. 46%). This representation does not follow through to the 
three case groups, with two of the groups having more males than females; no-show: 
48% female vs. 52% male; cancelations: 52% female vs. 48% male; combined: 
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combined: 35% female vs. 65% male. The vast majority of the patients spoke English 
(85%), with an extremely diverse range of other languages spoken. English-speaking 
patients also were a part of 85%, 88% and 85% of the no-show, cancelation and 
combined groups, respectively. Spanish and Haitian Creole were the only other languages 
to have patients in all three case groups.  
Patients aged 51-80 years old encompassed 90% of the total population, 93% of 
the no-show group, 97% of the cancelation group and 95% of the combined group, 
respectively. 18% of patients were newly diagnosed with lung cancer, less than 100 days 
since diagnosis in the total population (8% 0-24 days, 5% 25-49 days, 5% 50-99 days). In 
the no-show, cancelation and combined groups, 25% of the patients were newly 
diagnosed (no-show: 10% 0-24 days, 5% 25-49 days, 10% 50-99 days; cancelation: 11% 
0-24 days, 3% 25-49 days, 11% 50-99 days; 10% 0-24 days, 5% 25-49 days, 10% 50-99 
days).   13% of patients were 100-199 post diagnosis in the total populations, while 28% 
of patients in the no-show, 22% of patients in the cancelation group and 40% of the 
patients in the combined group were 100-199 days post-diagnosis. Patients over 1000 
days post diagnosis comprised of 26% of the total population (15% 1000-1999 days, 8% 
2000-2999 days, 3% 3000-3999 days). Patients 1000 days or more post diagnosis were 
13%, 14% and 10% of the no-show, cancelation and combined groups, respectively (no-
show: 8% 1000-1999 days, 2.5% 2000-2999 days, 2.5% 3000-3999 days; cancelation: 
9% 1000-1999 days, 2% 2000-2999 days, 3% 3000-3999 days; 5% 1000-1999 days, 5% 
2000-2999 days, 0% 3000-3999 days). 
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Patients with adenocarcinoma comprised 16%, squamous cell carcinoma 14% and 
SCLC 7% of the total population, respectively. In the case groups, the breakdown of 
patients was such that; in the no-show group, 33% of patients had adenocarcinoma, 15% 
squamous cell carcinoma and 10% SCLC; in the cancelation group, 19% had 
adenocarcinoma, 15% squamous cell carcinoma and 13% SCLC; in the combined group, 
25% had adenocarcinoma, 25% squamous cell carcinoma and 15% SCLC. Stage IA and 
IV cancers were the most prevalent in the total population, with 34% and 23%, 
respectively. In the case groups, this held true for the no-show and cancelation groups 
with 15% and 28% of the Stage IA and 38% and 33% of the Stage IV, respectively. The 
most prevalent tumor locations in the total population were lower lobe (24%) and right 
lung (26%). In the no-show, cancelation and combined groups, upper lobe (60%, 55% 
and 55%, respectively) and left lung (43%, 30% and 50%, respectively) were the most 
prevalent. Medicare was the most common insurance in all 4 groups; total population-
54%; no-show-45%; cancelation-48%; combined-45%.  The patient navigation 
population made up 17% of the total population, comprised of 35% of the no-show 
group, 31% of the cancellation group and 45% of the combined group, respectively. 
Table 3. Characteristics of Lung Cancer Patients at BMC for October-December 
2012 
Patient Characteristic Total 
No. of 
subj. 
No-show 
No. of 
subj. 
Cancelations 
No. of 
subj. 
Combined 
No. of 
subj. 
Overall 195 40 64 20 
Race     
American Indian 1 0 0 0 
Asian 7 2 3 2 
Black 75 16 21 7 
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Patient Characteristic Total 
No. of 
subj. 
No-show 
No. of 
subj. 
Cancelations 
No. of 
subj. 
Combined 
No. of 
subj. 
Race (cont.)     
Hispanic/Latino 8 3 4 2 
Middle Eastern 1 0 0 0 
Other 7 0 0 0 
White 96 19 36 9 
Sex     
Female 106 19 33 7 
Male 89 21 31 13 
Primary Language Spoken     
Albanian 3 1 0 0 
Arabic 2 0 0 0 
Bengali/Hindi/Urdu 1 1 0 0 
Chinese 2 0 0 0 
English 165 34 56 17 
Greek 1 0 0 0 
Haitian Creole 4 1 2 1 
Italian 1 0 0 0 
Port Creole/Cape Verdean 2 0 0 0 
Portuguese 1 0 0 0 
Russian 1 0 0 0 
Spanish 7 3 5 2 
Vietnamese 5 0 1 0 
Age (years)     
35-40 2 0 0 0 
41-45 2 1 0 0 
46-50 2 1 0 0 
51-55 20 6 8 4 
56-60 28 7 13 5 
61-65 41 10 19 6 
66-70 38 9 13 4 
71-75 28 2 5 0 
76-80 20 3 4 1 
81-85 9 1 1 0 
86-90 4 0 1 0 
>90 1 0 0 0 
Time Since Diagnosis (Days)     
0-24 15 4 7 2 
25-49 9 2 2 1 
50-99 9 4 7 2 
100-199 25 11 14 8 
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Patient Characteristic Total 
No. of 
subj. 
No-show 
No. of 
subj. 
Cancelations 
No. of 
subj. 
Combined 
No. of 
subj. 
Time Since Diagnosis (cont.)     
200-299 13 3 5 2 
300-399 16 3 5 2 
400-499 10 0 3 0 
500-599 10 1 3 0 
600-699 5 1 1 0 
700-799 8 1 0 0 
800-899 8 2 1 0 
900-999 8 2 2 0 
1000-1999 30 3 6 1 
2000-2999 15 1 1 1 
3000-3999 5 1 2 0 
Cancer Type     
Adenocarcinoma 32 9 12 5 
Carcinosarcoma 1 0 0 0 
NSCLC-NOS 14 2 5 1 
Squamous Cell Carcinoma 28 6 9 5 
SCLC 14 4 8 3 
Cancer Stage     
IA 67 6 18 1 
IB 24 4 7 2 
IIA 4 1 0 0 
IIB 15 2 3 2 
IIIA 21 6 9 5 
IIIB 19 5 6 3 
IV 44 15 21 7 
Tumor location     
Lower lobe 47 12 19 7 
Main stem bronchus 1 0 1 0 
Middle lobe 7 0 2 0 
Upper lobe 19 24 35 11 
Bilateral lungs 4 0 2 0 
Left lung 48 17 19 10 
Right lung 51 8 15 6 
Insurance Status     
Charity 2 0 0 0 
Commercial/Private 40 6 12 2 
Medicaid 41 12 16 6 
Medicare 105 18 31 9 
Multiple 2 2 1 1 
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Patient Characteristic Total 
No. of 
subj. 
No-show 
No. of 
subj. 
Cancelations 
No. of 
subj. 
Combined 
No. of 
subj. 
Patient Navigation      
Yes 33 14 20 9 
No 162 26 64 11 
 
 
Nonadherence 
Table 4 displays the odds ratios for nonadherence with outpatient appointments 
comparing each of the case groups to the control groups.  Odds ratios that could not be 
calculated due to a zero cell were marked as “--.”  Subject characteristics with odds ratios 
that could not be calculated across all three case groups were not included in Table 4.  
Race, sex and primary language spoken were not significant indicators of nonadherence. 
A nonsignificant trend was found showing increased odds for Asian and Hispanic/Latino 
subjects in all three nonadherence categories.  Though also nonsignificant, female 
subjects had lower odds than males of being nonadherent to appointments in all three 
categories.  Haitian Creole and Spanish speaking subjects were at nonsignificantly higher 
odds of being nonadherent with outpatient appointments across all three nonadherence 
categories.  Black females (data not shown) had significantly decreased odds of canceling 
multiple appointments (OR: 0.39, 95% CI: 0.15, 0.99, p-value: 0.048) when compared to 
white females.  A multivariate analysis combining race and sex did not yield any other 
results that differed from the univariate analysis. There were no other significant data 
when race and sex were combined.  
Age was not significantly associated with the odds of being a no-show or 
cancelling appointments.  Individuals aged 71-75 were found to have significantly lower 
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odds of canceling appointments, at one quarter the odds (95% CI: 0.08, 0.79).  Subjects 
aged 66-70 and 76-80 showed a nonsignificant trend of lower odds of nonadherence 
across the three case groups. There were many ORs that could not be calculated when 
looking at ages below 50 or above 80, as there were no individuals under the age of 50 
with a canceled appointment or in the combined group, and there were no subjects in the 
combined group above the age of 80. As age increased, the odds of nonadherence 
generally decreased. 
Time since diagnosis was not significantly associated with the odds of 
nonadherence until a patient was 1000 days post diagnosis.  Patients less than 50 days 
and 200-399 days post diagnosis, showed a nonsignificant trend of lower odds of 
nonadherence in all three case groups. Patients 500-699 and 800-999 days post diagnosis 
showed nonsignificant decreased odds for canceling and being no-shows to outpatient 
appointments.  Patients 1000-1999 days post diagnosis were at significantly deceased 
odds of being no-shows (OR: 0.14, 95% CI: 0.03, 0.59), canceling (OR: 0.20, 95% CI: 
0.06, 0.65) and both (OR: 0.07, 95% CI: 0.008, 0.64).  Patients 2000-2999 days post 
diagnosis were also at significantly decreased odds of being no-shows (OR: 0.09, 95% 
CI: 0.01, 0.80) or canceling multiple appointments (OR: 0.06, 95% CI: 0.006, 0.50). 
There was no significant association between cancer type or stage I and II lung 
cancer and nonadherence with outpatient appointments.  Patients with unspecified 
NSCLC (NSCLC-NOS) were at decreased odds of nonadherence, while patients with 
SCLC were at increased odds of nonadherence across the three case groups.  Patients 
with stage IB, IIA and IIB patients had increased odds of being no-shows.  Stage IIIA 
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(OR: 4.07, 95% CI: 1.15, 14.41) and IV (OR:  5.26, 95% CI: 1.85, 14.95) patients were at 
significantly higher odds of being no-shows. Stage IV patients were also significantly 
more likely to cancel multiple appointments (OR: 1.49, 95% CI: 1.12, 5.54).  Stage IIIA 
(OR: 20.63, 95% CI: 2.25, 189.04), IIIB (OR: 12.38, 95% CI: 1.21, 126.96) and IV (OR: 
12.49, 105.46) patients all had significantly higher odds of being in the combined case 
group. 
The location of a patient’s tumor was not significantly associated with 
nonadherence, except for right lung tumors and no-show rates. Patients with right lung 
tumors were at decreased odds of nonadherence across all three case groups, and the odds 
of being a no-show were significantly decreased (OR: 0.34, 95% CI: 0.13, 0.89).  Patients 
with upper lobe tumors were nonsignificantly at decreased odds of nonadherence.  
  There were no significant trends among patients’ insurance statuses.  In groups 
in which information was available to analyze, it was found that patients receiving the 
funding for their healthcare through charity were at decreased odds of canceling 
appointments.  Patients with Medicaid were at increased odds for nonadherence across all 
three categories.  
All odds ratios in the patient navigation category were significant.  Patients with 
navigators had 3.85 times the odds of being a no-show (95% CI: 1.72, 8.65), 4.13 times 
the odds of canceling multiple appointments (95% CI: 1.89, 9.00) and 5.15 times the odds 
of being both (95% CI: 1.93, 13.72).  The p-values (not shown) for these ORs were all 
<0.001. 
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Table 4: Odds Ratios Comparing the Case Populations to the Total Lung Cancer 
Population at BMC 
Patient Characteristic No-Show 
OR 
95% CI 
Cancelations 
OR 
95% CI 
Combined 
OR 
95% CI 
No. of subjects 40 64 20 
Race    
Asian 1.62  
(0.29, 9.01) 
1.25  
(0.26, 5.91) 
3.87  
(0.65, 22.88) 
Black/African American 1.10  
(0.52, 2.32) 
0.65  
(0.34, 1.24) 
1.00  
(0.35, 2.81) 
Hispanic/Latino 2.43  
(0.53, 11.08) 
1.67  
(0.39, 7.08) 
3.22  
(0.56, 18.38) 
White reference reference reference
Sex    
Female 0.71  
(0.35, 1.42) 
0.85  
(0.46, 1.54) 
0.41  
(0.16, 1.09) 
Male reference reference reference 
Primary Language Spoken    
Albanian 1.93  
(0.35, 1.42) 
-- -- 
English reference reference reference 
Haitian Creole 1.28 
 (0.13, 12.74) 
1.95  
(0.27, 14.19) 
2.90  
(0.29, 29.48) 
Port Creole/Cape 
Verdean 
-- 0.75  
(0.05, 12.24) 
-- 
Spanish 2.89  
(0.62, 13.53) 
4.87  
(0.91, 25.88) 
3.48  
(0.63, 19.35) 
Vietnamese -- 0.49  
(0.05, 4.46) 
-- 
Age (years)    
41-45 3.10  
(0.18, 54.24) 
-- -- 
46-50 3.10  
(0.18, 54.24) 
-- -- 
51-55 0.33  
(0.40, 4.38) 
0.77 
 (0.26, 2.28) 
1.46  
(0.36, 5.89) 
56-60 1.03 
(0.34, 1.35) 
1.00  
(0.38, 2.63) 
1.27  
(0.35, 4.64) 
61-65 reference reference reference
66-70 0.96  
(0.34, 2.70) 
0.60 
 (0.24, 1.49) 
0.69 
 (0.18, 2.65) 
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Patient Characteristic No-Show 
OR 
95% CI 
Cancelations 
OR 
95% CI 
Combined 
OR 
95% CI 
Age (cont.)    
71-75 0.24 
 (0.05, 1.19) 
   0.25*   
 (0.08, 0.79) 
-- 
76-80 0.55 
 (0.13, 2.26) 
0.29 
 (0.08, 1.02) 
0.31  
(0.03, 2.74) 
81-85 0.39 
 (0.04, 3.49) 
0.14 
 (0.02, 1.26) 
-- 
86-90 -- 0.39  
(0.04, 4.03) 
-- 
Time Since Diagnosis 
(Days) 
   
0-24 0.46 
 (0.12, 1.86) 
0.69  
(0.19, 2.49) 
0.33 
 (0.06, 1.81) 
25-49 0.36  
(0.06, 2.11) 
0.22 
 (0.04, 1.30) 
0.27  
(0.03, 2.50) 
50-99 1.02  
(0.22, 4.72) 
2.75  
(0.47, 15.96) 
0.61  
(0.10, 3.61) 
100-199 reference reference reference 
200-299 0.38 
 (0.08, 1.73) 
0.49 
 (0.13, 1.93) 
0.39 
 (0.07, 2.17) 
300-399 0.29 
 (0.07, 1.29) 
0.36 
 (0.10, 1.34) 
0.30  
(0.06, 1.67) 
400-499 -- 0.34  
(0.07, 1.61) 
-- 
500-599 0.14 
 (0.02, 1.29) 
0.34 
 (0.07, 1.61) 
-- 
600-699 0.32 
 (0.03, 3.27) 
0.20  
(0.02, 2.02) 
-- 
700-799 0.18 
 (0.02, 1.71) 
-- -- 
800-899 0.42  
(0.07, 2.53) 
0.11  
(0.01, 1.05) 
-- 
900-999 0.42 
 (0.07, 2.53) 
0.26 
 (0.04, 1.56) 
-- 
1000-1999  0.14 ** 
(0.03, 0.59) 
   0.20** 
(0.06, 0.65) 
  0.07* 
 (0.01, 0.64) 
2000-2999 0.09** 
 (0.01, 0.80) 
  0.06** 
 (0.01, 0.50) 
0.15 
 (0.02, 1.36) 
3000-3999 0.32 
 (0.03, 3.27) 
0.52 
 (0.07, 3.70) 
-- 
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Patient Characteristic No-Show 
OR 
95% CI 
Cancelations 
OR 
95% CI 
Combined 
OR 
95% CI 
Cancer Type    
Adenocarcinoma reference reference reference 
NSCLC-NOS 0.43 
(0.08, 2.29) 
0.93 
 (0.25, 3.42) 
0.42 
 (0.04, 3.93) 
Squamous Cell 
Carcinoma 
0.70 
 (0.21, 2.28) 
0.79 
 (0.27, 2.30) 
1.17  
(0.30, 4.57) 
SCLC 1.02 
 (0.25, 4.11) 
2.22 
 (0.62, 7.97) 
1.47 
 (0.02, 1.36) 
Cancer Stage    
IA reference reference reference 
IB 2.03 
 (0.52, 7.94) 
1.12  
(0.40, 3.15) 
6.00 
 (0.52, 69.43) 
IIA 3.39 
 (0.30, 37.87) 
-- -- 
IIB 1.56 
 (0.28, 8.63) 
0.68 
 (0.17, 2.69) 
10.15  
(0.86, 120.41) 
IIIA 4.07 
(1.15, 14.41) 
2.04 
(0.74, 5.66) 
20.63 
(2.25, 189.04) 
IIIB 3.63 
 (0.97, 13.61) 
1.26 
 (0.41, 3.80) 
12.38* 
 (1.21, 126.96) 
IV 5.26** 
 (1.85, 14.95) 
2.49* 
 (1.12, 5.54) 
12.49* 
 (1.48, 105.46) 
Tumor location    
Lower lobe reference reference reference 
Middle lobe -- 0.59 
 (0.10, 3.36) 
-- 
Upper lobe 0.72  
(0.33, 1.60) 
0.60 
 (0.30, 1.21) 
0.57 
 (0.21, 1.58) 
    
Bilateral lungs -- 1.53 
 (0.20, 11.78) 
-- 
Left lung reference reference reference 
Right lung 0.34* 
(0.13, 0.89) 
0.64 
 (0.28, 1.47) 
0.51 
 (0.17, 1.52) 
Insurance Status    
Commercial/Private reference reference reference 
Medicaid 2.34 
 (0.78, 7.03) 
1.49  
(0.59, 3.76) 
3.26 
 (0.62, 17.21) 
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Patient Characteristic No-Show 
OR 
95% CI 
Cancelations 
OR 
95% CI 
Combined 
OR 
95% CI 
Insurance Status (cont.)    
Medicare 1.17  
(0.43, 3.20) 
0.98 
 (0.44, 2.17) 
1.78 
 (0.37, 8.63) 
Multiple -- 0.56 
 (0.13, 40.47) 
19.00 
 (0.84, 428.26) 
Patient Navigation     
Yes 3.85** 
(1.72, 8.65) 
4.13** 
 (1.89, 9.00) 
5.15** 
 (1.93, 13.72) 
No reference reference reference
 *: p<0.05, **: p<0.01;	Note: Some patient characteristic groups were left out due to the 
inability to calculate an OR with a zero cell. 
	
Patient Navigation 
 There were no significant odds ratios identified when the patient navigation group 
(n=33) was analyzed.  The data was stratified by all ten patient characteristics. Odds 
ratios for primary language spoken could not be analyzed due to zero cells in all 
languages except English. The odds ratios can be found in Appendix II.   
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DISCUSSION 
	
The groups at highest risk for nonadherence with outpatient appointments can be 
identified in order to reduce the number of no-shows and cancelations, to reduce the time 
interval between diagnosis and treatment and reduce the cost associated with missed 
appointments.  This can be accomplished by adding the high risk groups to the patient 
navigation system.  One of the roles of the patient navigators is to follow patients closely 
to assure that if patients cannot make an appointment they cancel a reasonable amount of 
time before the appointment, allowing time to reschedule, rather than simply missing the 
appointment altogether.36  Patient navigators have close relationships with the patients 
they are helping and do much more than just help cancel appointments. Patient navigators 
facilitate appointment scheduling, scheduling interpreters, helping to schedule/providing 
logistics for transportation to appointments, and other jobs.36 
The appointment types with the highest nonadherence rates were oncology and 
chemotherapy appointments.  Oncology appointments accounted for 34% of no-show and 
38% of canceled appointments, while chemotherapy accounted for 25% and 24% of no-
show and canceled appointments, respectively (Appendix III).  In the total population, 
oncology and chemotherapy accounted for 35% and 18% of the appointments 
respectively. These large percentages were expected given that the population studied 
was lung cancer patients.  It is interesting to note that the majority of patients (75%) only 
had one no-show and only two patients had more than 2 no-shows over the three month 
study period.  These two patients were included in the group of patients with the most 
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total appointments patients with the most total appointments, 9 or more.  There were only 
21% of patients with more than 5 appointments and 8% with 9 or more.  Of the 271 
canceled appointments, 143 (53%) were rescheduled.  Due to the limitations of a de-
identified dataset, it could not be determined whether the appointment was rescheduled 
during the 3 month study period.  It could also not be determined whether appointments 
were canceled and rescheduled by patient navigators or the patients. One trend that was 
noted in the appointment data was that as the number of appointments a patient had 
increased, their percentages of cancelations increased as well. Many of the patients with 
7-17 appointments canceled more than 50% of the time.  
No studies could be found that specifically examined appointment adherence in 
lung cancer patients.  Papers evaluating attendance at primary care visits were used as 
comparisons to the associations found in this study. No other specific medical specialties 
were used as that may have added another confounding variable. Very few papers looked 
at cancelations or cancelations were included with patients who attended their 
appointments. For many clinical practices following patients who cancel multiple 
appointments, is not very important.  This group is very important in oncology, because 
canceling multiple appointments in a short period of time can delay treatment.  Delays in 
treatment can lead to cancer progression.42 
There were some demographic groups for which analyses could not be done due 
to the fact that none of the patients appeared in the case groups.  As such, no association 
could be made between these groups and nonadherence with outpatient appointments.  In 
the study population, there was only one American Indian and one Middle Eastern patient 
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and neither of those patients were nonadherent. The same was true for patients who spoke 
Arabic, Chinese, Greek, Italian, Port Creole/Cape Verdean, Portuguese and Russian with 
only 1 or 2 patients speaking each of these languages in the total study population. No 
patients above the age of 90 or aged 40 or below appeared in any of the case groups. It is 
not unexpected for these groups to be so small, as less than 2% of patients are diagnosed 
before age 40 and about 92% of cases are diagnosed before age 85.44  There was only one 
case of carcinosarcoma in the total population. This is not surprising as carcinosarcomas 
are rare pulmonary malignancies.45  The last group that was too small for analyses to be 
done was the group that had charity listed as insurance type.  
The lack of significant associations in the majority of race, sex and primary 
language spoken categories demonstrates that these characteristics are not highly 
associated with whether or not a lung cancer patient will attend their outpatient 
appointments. The case of black females having significantly decreased odds of canceling 
multiple appointments barely meets the requirements for significance with a p-value of 
0.048.  With no literature on cancelations, no reasoning behind this result could be found.  
This result may be due to chance, as the only decreased odds in the race category.  Asian 
and Hispanic/Latino patients had nonsignificantly increased odds of nonadherence across 
all three case groups.  This finding is partially supported by a study done in primary care 
clinics by Kaplan-Lewis and Percac-Lima46 showing that Hispanic patients in Boston are 
at the highest risk of being no-shows.  Though this study does not use cancer patients, so 
there are some differences in the populations, the populations do come from the same 
urban area and were most likely very similar.46  
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The results of this case-control study also showed nonsignificant lower odds of 
nonadherence in women in all three case groups. The majority of research done on 
adherence with outpatient appointments agrees with this finding.  Frankel, Farrow and 
West conducted a case-control study across six outpatient specialties at one hospital and 
found that males were more likely to be no-shows than females, though not 
significantly.47  The authors also found that males were 43% of the no-show groups, 
versus 38% of the adherent group.  A study48 of all Scottish outpatient appointments over 
a three year time period, 2008 through 2010, found that no-show rates were higher in 
males than females. This was an extremely large sample size with over 4.5 million 
appointments.48  A world-wide literature review of scientific papers by George and 
Rubin24, looking at the epidemiology of no-shows and interventions to increase 
adherence found higher no-show rates in men than women. This study was done across 
all medical disciplines and had an extremely large sample size.24  The sample size in this 
case-control study conducted may have been too small to see a significant OR for sex in 
any of the case groups.  A literature search was conducted and no papers could be found 
to support the cancelation data.   
Though there were no significant results for primary language spoken, patients 
who spoke Haitian Creole and Spanish had higher odds of nonadherence in all three case 
groups. As the majority of the Hispanic/Latino patients were Spanish speaking, the 
results are consistent with an overlap with the nonsignificant increase in odds of 
Hispanic/Latino patients across all three case groups.  No literature could be found with 
results on the adherence of Haitian Creole speaking patients to outpatient appointments. 
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While not a significant portion of the population in the United States, these patients do 
make up a large portion of the patients at BMC, making these results extremely 
important.  
Previous research supports the finding that younger patients are more likely to be 
nonadherent with outpatient appointments.46, 49, 50 For the most part, the results of this 
study follow this trend, with patients younger than 61-65 years old having higher odds of 
no-shows and patients older than 61-65 years old having lower odds of being no-shows. 
The exception to this is patients 51-55 years old with an OR of 0.33.  This result differs 
from the literature which shows that the younger the patients the higher their odds of a 
no-show.49  Guita et. al demonstrated that patients over the age of 65 had decreased odds 
of being no-shows.49 Their study included all outpatient appointments in the hospital, not 
just oncology or pulmonology related appointments.49  Another study also demonstrated 
that for every one year increase in age there was a OR of 0.98 (p<0.001).50  The 
cancelation group, and the results that could be calculated, for the combined group in this 
case-control study, showed the same trend.  Patients 71-75 years of age showed 
significant decreased odds of canceling multiple appointments (p=0.018).  Though these 
results cannot be confirmed by the literature, as there is very little published on 
cancelations, there is no reason to think that this data is not valid.  
The results for the association between time since diagnosis and nonadherence 
were hard to analyze. There were no significant results until 1000 days post diagnosis.  
At this stage, most patients have completed treatment and are being followed every few 
months to 1 year to check for a recurrence of the cancer. Using 100-199 post diagnosis as 
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the reference for calculating the ORs resulted in almost all ORs less than 1, except at 50-
99 days and 1000-1999 days post diagnosis.  The OR of 2.75 in the cancelation group at 
50-99 days may not be a result to be taken seriously, as it is the only high OR.  The 
meaning of the significant results for the patients 1000-2999 post diagnosis was also hard 
to interpret. These patients ranged from 2.7 to 8.2 years post diagnosis. While the 
decreased ORs for noncompliance across all three case groups were not surprising, as 
patients most likely wanted to make sure their cancer had not returned, it was odd that 
only this group of patients had significant results. It could be due to the fact that these 
groups represented larger portions of the total population than others and other groups of 
patients at different stages had too small of a sample size to show statistical significance.  
Cancer type did not show any significant association with nonadherence.  
NSCLC-NOS and Squamous cell carcinoma had decreased ORs for no-shows when 
compared to the reference, adenocarcinoma. SCLC had an increased OR across all three 
case groups, though the OR for the no-show group showed a very minor increase.  The 
increase in ORs for SCLC was not surprising due to the fact that SCLC is a more 
aggressive form of cancer, with a poorer prognosis. Patients, who perceive their illness as 
having a worse prognosis, tend to be less adherent to their outpatient appointments.24  
This may also be due to the symptoms of lung cancer, as SCLC is a much more 
aggressive form of cancer than NSCLC.11 Patients who feel ill are less likely to show up 
for their appointments.28 
All stages of lung cancer had an increased OR for nonadherence when compared 
to stage IA lung cancer.  Stage IIIA and IV patients had a significantly increased OR for 
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being a no-show (p=0.030; p=0.0018). Stage IIIB patients also had a borderline 
significantly increased OR for being a no-show with a 95% CI of 0.97, 13.61 and a p-
value of 0.056.  As stated above, patients who do not view themselves as having a good 
prognosis tend to no-show more frequently24 therefore, these results were expected.  
Stage IIIA, IIIB and IV patients also had significantly increased ORs for the combined 
case population (p=0.0074; p=0.034; p=0.020). The extremely large 95% CI for these 
results implies poor precision and may be due to the small sample size.  Stage IV patients 
also had a significantly increased OR for the multiple cancelation case group (p=0.026).  
None of the Stage IV data is surprising given the poor prognosis of the patients24 and the 
fact that they are much sicker than early stage patients.28 
The location within the lung was examined to determine if there was an 
association with nonadherence.  Patients with upper lobe and right lung cancer had lower 
ORs for nonadherence than patients with lower lobe and left lung cancer across the three 
case groups.  Patients with right lung cancer were significantly less likely to no-show 
than left lung cancer patients (p=0.027).  These right lung results disagree with data that 
suggest that right lung SCLC tumors are associated with a worse prognosis and as stated 
earlier, patients with a worse prognosis tend to have a higher likelihood of being a no-
show.24, 51  The majority of the patients in this study were not SCLC patients, but NSCLC 
patients, so their data was influencing the results more when not stratified by cancer type.  
No data was available on the differences in prognosis, if any exist, for different locations 
of NSCLC tumors. There was no way to know if the results for the association between 
lung cancer location and nonadherence were valid. No literature was found on NSCLC to 
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support the results and without the results stratified by cancer type, the SCLC data cannot 
be separately analyzed to determine agreement with the existing literature.  
When the patients were stratified by insurance type, there were no significant 
associations.  Medicaid patients had nonsignificantly increased OR in all three case 
groups. This agreed with the literature that stated that patients with Medicaid were more 
likely to no-show.46  One study also found that lower socio-economic status and reliance 
on government funded insurance increased the possibility of being a no-show.24  In order 
to qualify for Medicaid, adults with 1-5 children in Massachusetts had to have made less 
than 150% the federal poverty level.52  The federal poverty level in 2012 was $23,050.53 
The most significant results of the study came from stratifying the patients based 
on patient navigation status.  All of the results in this analysis were statistically 
significant.  These results showed that in each case group, the patients that were 
nonadherent had higher odds of being in the patient navigation program.  This result was 
not unexpected for the cancelation and even combined case groups.  The number of 
canceled appointments far outweighed the number of no-show appointments and 
therefore had a greater influence on the results.  One of the tasks of the patient navigators 
is to help patients cancel appointments if they will be unable to attend, in order to both 
identify another appointment time that will work for the patient and to prevent the patient 
from no-showing. This allows the appointment to be used by another patient. So, it was 
expected that the number of cancelations would be higher in those groups.  The 
significant increase in the odds of being a no-show in the patient navigation category was 
surprising.  The patient navigators should be contacting patients before their 
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appointments to not only remind them, but to make sure the patients are able to make it to 
their appointments.  This should lead to a reduction in no-shows and an increase in 
cancelations over the population without navigators.  This result shows that there may 
have been a deficiency somewhere in the lung cancer patient navigation at BMC. It may 
also indicate that these patients, having already been identified as having barriers to care 
and therefore having been referred to the patient navigators, continued to struggle with 
barriers to keeping appointments.  It is important to follow these patients over time to 
determine if the patient navigation system is helping these patients. 
The previous results do not mean that the program is not working at all. The 
analysis of the patient navigation patients (Appendix II) shows that no patient 
characteristic groups within the program had a statistically significant difference in the 
odds of being nonadherent.  When comparing these results to Table 4, it could be seen 
that many results went from increased odds of nonadherence to decreased odds in the 
patient navigation category.  Many of these decreases were in groups that had significant 
increases in odds in the analysis in Table 4. 
The effect of patient navigation on the association between language spoken and 
nonadherence was not able to be ascertained due to the lack of any languages without a 
zero cell for any language other than English.  The patient navigation moved the odds of 
a no-show within the black population from increased odds to decreased odds.  The same 
trend continued for patients aged 51-60, with the odds falling from above 1.00 to below 
1.00 in the combined category.  The helpfulness of the patient navigation program is 
especially apparent when looking at the results for cancer stage.  Stage IV patients have 
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barely increased odds of being a no-show within the patient navigation group. This is a 
vast improvement over the total population in which stage IV patients had over 5 times 
the odds of being a no-show.  A similar trend continued for the combined group for stage 
IV patients, where patients had decreased odds within the patient navigation category and 
had over 12 times the odds of being in the combined group in the total population. While 
the stage IIIA patients’ odds of being a no-show did not decrease by being in patient 
navigation, the odds did decrease from 20.63 to 4.00 in the combined category.  The 
same trend followed for stage IIB patients.  These results show that later stage patients, 
with a poorer prognosis, can be adherent with help from patient navigators.  Another 
population that the patient navigation is helping is those with Medicaid. In the total 
population, the odds of a no-show were higher in patients with Medicaid than those with 
private insurance, and with patient navigation, those odds have dropped to lower than 
those with private insurance.  Patient navigation seemed to have a questionable effect on 
the odds between squamous cell carcinoma and being a no-show. The odds of being a no 
show increased from below 1.00, at 0.70, to 4.50 when patients moved into the patient 
navigation program.  It is important to identify why this relationship exists.  Medical 
practitioners, patient navigators and patients themselves, would not want anyone entering 
into a program that could end up increasing their odds of being a no-show and increase 
their chances of a delay in treatment.  
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Limitations 
Though this study has many limitations, there is no reason to believe that they had 
any effect on the validity of the results. Due to the nature of a case-control study, no 
causal relationships could be determined.  However, a case-control study was the best 
design for this type of research and the associations found provide solid evidence. One of 
the largest limitations of this study was the data itself. Due to the de-identified nature of 
the dataset, it was impossible to go into the medical records to find information that was 
missing when the data set was received. This could have skewed that data to be slightly 
underestimated for some patient characteristics.  This should not have greatly affected the 
results, because there were no groups with increased odds, that were not already 
statistically significant, near enough to statistical significance that a few missing values 
would have pushed the odds to significance. Therefore the missing value did not allow 
for any at risk groups to be missed.  The de-identified nature of the dataset limits the 
ability to see why patients did not come to their appointments.  The patient navigators 
designate in their notes in the medical records many of the reasons behind the patients’ 
cancelations and no-shows. A lot more research could have been done and conclusions 
could have been made if the reasons behind the nonadherence could be investigated. 
Another limitation was with the electronic medical record system.  Deceased patients 
were not always immediately entered into the system as deceased. At the time of a no-
show it is possible that a patient was actually deceased and their status had not yet been 
changed in the records. This however, was not an extremely common occurrence and 
should not have had a large impact on the no-show data. There was also no way to tell, 
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with the patients years past diagnosis, if their visits to the oncologist and pulmonologist 
were due to their lung cancer or another condition, such as a new cancer. It was assumed 
that all visits to the oncologist were follow-up lung cancer visits as most patients in 
remission have at least yearly checks to make sure their cancer has not recurred.  Lastly, 
non lung cancer patients with lung metastases were included in the original data set. 
These patients were able to be removed due to different staging such as IE, a lymphoma 
stage, making them distinct from the lung cancer patients.54 There is the possibility that a 
one or more non lung cancer patients who could not be separated remained in the study 
population.  This should not have affected the results to a great degree due to the fact that 
this could not have resulted in more than a few non lung cancer patients, if any, being left 
in the study population. 
 
Conclusions 
This study has shown that there are certain patient groups that are at higher risk of 
being nonadherent to lung cancer outpatient appointments. Among those are 
Hispanic/Latino patients, Spanish and Haitian Creole speaking patients, SCLC patients, 
patients with Medicaid, and patients with late stage lung cancer.  It is important to 
address these results to ensure that every cancer patient gets the best treatment possible 
and can overcome any barriers they may have.  Patients who no-show and cancel 
multiple appointments over a short period of time may experience a delay of treatment. It 
is important to mitigate this, by reducing these numbers.  The patient navigation program 
can have a positive impact in this area.  While this study has shown that the lung cancer 
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patient navigation program may need to be evaluated to improve effectiveness, it has also 
shown that the program is helping the groups of patients identified as high risk, in 
addition to others.  It may also be helpful to look at the groups of patients at extremely 
decreased odds of nonadherence, without other risk factors, such as patients aged greater 
than 80 and patients greater than 1000 days post diagnosis. If these patients are in the 
patient navigation system, it may be more useful to free up resources to help patients 
more at need of a navigator.   
 
Future Studies 
Follow-up studies need to be conducted to confirm the validity of these findings.  It 
would also be extremely useful to repeat this study without the limitations of a de-
identified dataset, as missing information could then be pulled from the medical records.  
A repeat of the study could also be done in another cancer type to determine if the same 
association between patient characteristics, nonadherence and patient navigation exists 
within other cancer populations.  It is hoped that this study will encourage further 
investigations into the patient navigation and nonadherence fields.  
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APPENDIX 
	
Appendix I: AJCC TNM Staging9 
Stage Description Notes 
TX Primary tumor cannot be assessed, or tumor 
proven by the presence of malignant cells in 
sputum or bronchial washings but not 
visualized by imaging or bronchoscopy 
 
T0 No evidence of primary tumor  
Tis Carcinoma in situ   
T1a Tumor  ≤2 cm in size, surrounded by lung 
or visceral pleura, without bronchoscopic 
evidence of invasion more proximal than 
lobar bronchus 
-Not in the main 
bronchus 
 
T1b Tumor 2-3 cm in size with or without the 
features  listed in T1a 
 
T2a Tumor with any of the following features of 
size or extent:  
-3-5 cm in size 
-Involves mean bronchus, 2 cm or more 
distal to the carina 
-Invades visceral pleura 
-Associated with atelectasis or obstructive 
pneumonitis that extends to the hilar region 
but does not involve the entire lung 
 
T2b Tumor 5-7 cm in size with  or without the 
other features listed in T2a 
 
T3 Tumor >7 cm that directly invades any of 
the following: chest wall (including superior 
sulcus tumors), diaphragm, mediastinal 
pleura, parietal pericardium; or tumor in the 
main bronchus less than 2 cm distal to the 
carina, but without involvement of the 
carina; or associated atelectasis or 
obstructive pneumonitis of the entire lung 
OR multiple tumor nodules in the same lobe 
 
T4 Tumor of any size that invades any of the 
following: mediastinum, heart, great vessels, 
trachea, esophagus, vertebral body, carina or 
multiple tumor modules in the same lung 
but in a different lobe 
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NX Regional lymph nodes cannot be assessed  
N0 No regional lymph node metastasis  
N1 Metastasis is ipsilateral peribronchial and/or 
ipsilateral hilar lymph nodes, and 
intrapulmonary nodes including 
involvement by direct extension of the 
primary tumor 
 
N2 Metastasis to ipsilateral mediastinal and/or 
subcarinal lymph nodes 
 
N3 Metastasis to contralateral mediastinal, 
contralateral hilar, ipsilateral or contralateral 
scalene, or supraclavicular lymph nodes 
 
   
MX Distant metastasis cannot be assessed  
M0 No distant metastasis  
M1a Malignant pleural or pericardial effusions 
present 
 
M1b Separate tumor nodules in the contralateral 
lung or distant metastases present 
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Appendix II: Patient Navigation nonadherence ORs for BMC lung cancer patients 
October-December 2012 
	
Patient Characteristic Total 
No. of 
subj. 
No-show 
No. of subj. 
OR  
(95% CI) 
Cancelations 
No. of subj. 
OR  
(95% CI) 
Combined 
No. of subj. 
OR  
(95% CI) 
Overall 33 14 28 12 
Race     
Black 13 
 
5 
0.89  
(0.20, 3.91) 
13 
-- 
5 
1.15 
(0.26, 5.11) 
Hispanic/Latino 3 2  
2.86 
(0.21, 37.99) 
2 
0.62 
(0.04, 8.70) 
1 
0.92 
(0.07, 12.32) 
White 17 7  
reference 
13 
reference 
6 
reference 
Sex     
Female 22 9  
0.83 
(0.19, 3.58) 
17 
-- 
7 
0.56 
(0.13, 2.48) 
Male 11 5  
reference 
11 5 
reference 
Age (years)     
51-55 4 2 
0.71 
(0.07, 6.92) 
2 
reference 
1 
0.24 
(0.02, 3.01) 
56-60 8 2 
0.24 
(0.03, 1.71) 
8 
-- 
2 
0.24 
(0.03, 1.71) 
61-65 12 7 
reference 
12 
-- 
7 
reference 
66-70 4 2 
0.71 
(0.07, 6.92) 
3 
3.00 
(0.15, 59.89) 
1 
0.24 
(0.02, 3.01) 
81-85 2 0 
-- 
1 
1.00 
(0.03, 29.81) 
0 
-- 
Time Since Diagnosis 
(Days) 
    
0-24 4 1 
0.08 
(0.003, 1.95) 
3 
reference 
1 
0.08 
(0.003, 1.95) 
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Patient Characteristic Total 
No. of 
subj. 
No-show 
No. of subj. 
OR  
(95% CI) 
Cancelations 
No. of subj. 
OR  
(95% CI) 
Combined 
No. of subj. 
OR  
(95% CI) 
Time Since Diagnosis 
(Cont.) 
    
25-49 5 1 
0.06 
(0.002, 1.39) 
3 
0.50 
(0.03, 8.95) 
0 
-- 
50-99 3 3 
-- 
 
2 
0.67 
(0.02, 18.06) 
2 
0.50 
(0.02, 12.90) 
100-199 5 4 
reference 
5 
-- 
4 
reference 
200-299 4 1 
0.08 
(0.004, 1.95) 
3 
1.00 
(0.04, 24.55) 
1 
0.08 
(0.003, 1.95) 
300-399 2 1 
0.25 
(0.007, 8.56) 
2 
-- 
1 
0.25 
(0.007, 8.56) 
800-899 3 1 
0.13 
(0.005, 3.22) 
3 
-- 
1 
0.13 
(0.005, 3.22) 
900-999 2 1 
0.25 
(0.007, 8.56) 
2 
-- 
1 
0.25 
(0.007, 8.56) 
Cancer Type     
Adenocarcinoma 10 4 
reference 
9 
reference 
4 
reference 
NSCLC-NOS 3 0 
-- 
 
2 
0.22 
(0.009, 5.28) 
0 
-- 
Squamous Cell 
Carcinoma 
4 3 
4.50 
(0.34, 60.15) 
4 
-- 
3 
4.50 
(0.34, 60.15) 
SCLC 4 2 
1.50 
(0.15, 15.46) 
3 
0.33 
(0.02, 7.14) 
2 
1.50 
(0.15, 15.46) 
Cancer Stage     
IA 6 2 
reference 
6 
-- 
2 
Reference 
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Patient Characteristic Total 
No. of 
subj. 
No-show 
No. of subj. 
OR  
(95% CI) 
Cancelations 
No. of subj. 
OR  
(95% CI) 
Combined 
No. of subj. 
OR  
(95% CI) 
Cancer Stage (Cont.)     
IB 3 1 
1.00 
(0.05, 18.92) 
1 
0.07 
(0.004, 1.12) 
0 
-- 
IIB 2 1 
2.00 
(0.08, 51.60) 
1 
0.13 
(0.006, 3.08) 
1 
2.00 
(0.08, 51.60) 
IIIA 3 2 
4.00 
(0.21, 75.66) 
3 
-- 
2 
4.00 
(0.21, 75.66) 
IV 17 6 
1.09 
(0.15, 7.80) 
15 
reference 
5 
0.83 
(0.11, 6.11) 
Tumor location     
Lower lobe 6 4 
reference 
6 
-- 
4 
reference 
Upper lobe 23 10 
0.38 
(0.06, 2.54) 
18 8 
0.27 
(0.04, 1.78) 
Left lung 13 8 
reference 
12 
reference 
8 
reference 
Right lung 9 3 
0.31 
(0.05, 1.85) 
7 
0.29 
(0.02, 3.83) 
3 
0.31 
(0.05, 1.85) 
Insurance Status     
Commercial/Private 2 1 
1.20 
(0.06, 24.27) 
0 
-- 
0 
-- 
Medicaid 11 5 
reference 
10 
reference 
5 
reference 
Medicare 17 6 
0.65 
(0.14, 3.08) 
15 
0.75 
(0.06, 9.42) 
5 
0.50 
(0.10, 2.43) 
The number of patients in each category may not sum to the total due to missing 
information and the small sample size of the patient navigation population compared to 
the total population. 
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Appendix III: Patient Appointment Breakdown 
total	
no.	of	
appts	
total	
no.	
of	
pts.	
no.	of	
pts.	
with	
no‐
shows	
(no.)	
location	of	no‐
shows	(no.)	
no.	of	pts.	
with	
cancelations	
(no.)	
location	of	
cancelations	
(no.)	
no.	of	
pts.	
with	
both	
1	 30	 0	 ‐‐	 0	 ‐‐	 0	
2	 51	 4	(1)	 hematology	
(2)	
oncology	(2)	
0	 ‐‐	 1	
3	 30	 7	(1)	 oncology	(2)	
thoracic	
surgery	(2)	
hematology	
(1)	
pulmonology	
(1)	
IMPAC	(1)	
3	(2)	
	
pulmonology	
(4)	
thoracic	
surgery	(2)	
3	
4	 28	 4	(1)	
1	(2)	
chemotherapy	
(2)	
pulmonology	
(2)	
oncology	(1)	
neurosurgery	
(1)	
4	(3)	
9	(2)	
oncology	(15)	
thoracic	
surgery	(5)	
rad.	oncology	
(3)	
hematology	(2)	
chemotherapy	
(2)	
IMPAC	(2)	
pulmonology	
(1)	
5	
5	
	
	
	
	
	
	
	
	
	
15	 3	(1)	
1(2)	
oncology	(1)	
chemotherapy	
(1)	
pulmonology	
(1)	
hematology	
(1)	
gen.	surgery	
(1)	
	
	
3	(3)	
5	(2)	
chemotherapy	
(8)		
thoracic	
surgery	(6)	
oncology	(4)	
rad.	oncology	
(1)	
2	
	51	
	
total	
no.	of	
appts	
total	
no.	
of	
pts.	
no.	of	
pts.	
with	
no‐
shows	
(no.)	
location	of	no‐
shows	(no.)	
No.	of	Pts.	
With	
cancelations	
(No.)	
Location	of	
Cancelations	
(No.)	
No.	of	
Pts.	
With	
Both	
6	 9	 1	(1)	 chemotherapy	
(1)	
5	(4)	
3	(3)	
1(2)	
oncology	(12)	
chemotherapy	
(10)	
thoracic	
surgery	(5)	
pulmonology	
(2)		
rad.	oncology	
(1)	
IMPAC	(1)	
1	
7	 12	 4	(1)	
3	(2)	
oncology	(5)	
chemotherapy	
(4)	
rad.	oncology	
(1)	
2	(5)	
3	(4)	
3	(3)	
3	(2)	
oncology	(15)	
chemotherapy	
(9)	
thoracic	
surgery	(6)	
rad.	oncology	
(3)	
hematology	(2)	
pulmonary	(2)	
6	
8	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
5	 3	(2)	 oncology	(3)	
chemotherapy	
(3)	
1	(5)	
3	(4)	
1	(3)	
oncology	(9)	
chemotherapy	
(7)	
thoracic	
surgery	(2)	
pulmonology	
(1)	
rad.	oncology	
(1)	
3	
	52	
	
total	
no.	of	
appts	
total	
no.	
of	
pts.	
no.	of	
pts.	
with	
no‐
shows	
(no.)	
location	of	no‐
shows	(no.)	
No.	of	Pts.	
With	
cancelations	
(No.)	
Location	of	
Cancelations	
(No.)	
No.	of	
Pts.	
With	
Both	
9	 5	 2	(1)	
1	(3)	
oncology	(2)	
chemotherapy	
(1)	
hematology	
(1)	
pulmonology	
(1)	
1	(6)	
1	(5)	
1	(4)	
2	(3)	
pulmonology	
(6)	
oncology	(6)	
chemotherapy	
(5)	
rad.	oncology	
(2)	
thoracic	
surgery	(1)	
hematology	(1)	
3	
10	 2	 1	(1)	 pulmonology	
(1)	
1	(8)	
1	(4)	
oncology	(5)	
chemotherapy	
(5)	
pulmonology	
(1)	
rad.	oncology	
(1)	
	
11	 6	 3	(1)	
1	(4)	
pulmonology	
(2)	
oncology	(1)	
chemotherapy	
(1)	
hematology	
(1)	
thoracic	
surgery	(1)	
rad.	oncology	
(1)	
1	(7)	
1	(6)	
2	(5)	
1	(4)	
1	(2)	
oncology	(12)	
chemotherapy	
(11)	
pulmonology	
(2)	
thoracic	
surgery	(1)	
gen.	surgery	
(1)	
hematology	(1)	
rad.	oncology	
(1)	
	
14	
	
	
	
	
1	 0	 ‐‐	 1	(9)	 oncology	(6)	
chemotherapy	
(2)	
thoracic	
surgery	(1)	
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total	
no.	of	
appts	
total	
no.	
of	
pts.	
no.	of	
pts.	
with	
no‐
shows	
(no.)	
location	of	no‐
shows	(no.)	
No.	of	Pts.	
With	
cancelations	
(No.)	
Location	of	
Cancelations	
(No.)	
No.	of	
Pts.	
With	
Both	
17	 1	 1	(1)	 oncology	(1)	 1	(10)	 thoracic	
surgery	(4)	
oncology	(2)	
chemotherapy	
(2)	
rad.	oncology	
(1)	
IMPAC	(1)	
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